Lv3
270 积分 2024-05-09 加入
Biologic degraders push forward in the clinic
2天前
已完结
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
7天前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
7天前
已完结
Site-specific construction of triptolide-based antibody-drug conjugates
1个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
皖公网安备34019202002308
